Antengene’s ATG-101 Receives the NMPA’s IND Approval for the Treatment of Solid Tumors and Non-Hodgkin Lymphoma
Shots:
- The NMPA has approved an IND application to initiate the P-I (PROBE-CN), dose-escalation, and a dose-expansion study to evaluate the safety and tolerability of ATG-101 (IV) in patients with advanced/ metastatic solid tumors and B-NHL
- In preclinical studies, the therapy showed significant anti-tumor activity in animal models of resistant tumors along with the patients on anti-PD-1/L1 treatment. The therapy demonstrated an excellent safety profile in GLP toxicology studies
- ATG-101 is a PD-L1/4-1BB bi-specific Ab that was designed to activate anti-tumor immune effectors by forming a cell-Ab-cell trimer to block the binding of PD-L1/PD-1 & induce 4-1BB stimulation
Ref: PR Newswire | Image: Antengene
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
